New CEO to transition Saniona to ‘full-fledged’ rare disease biopharma

New CEO to transition Saniona to ‘full-fledged’ rare disease biopharma
Rami Leven

Saniona, a Danish biotech company focused on rare diseases relating to eating disorders and the central nervous system (CNS), has industry veteran Rami Levin as CEO to oversee its transition to a fully-fledged biopharma with focus on rare diseases.

Mr Levin was appointed by the Board of Directors in close consultation with the founders of Saniona, Jørgen Drejer and Thomas Feldthus, based on his extensive relevant experience in bringing treatments for rare diseases to market, as well as in managing and building organizations in the US.

He also brings familiarity with Sweden and Scandinavia in general from previous roles as President, North America at Sobi and Managing Director of the Merck Group in Scandinavia.

Hr will be based in Boston. Jørgen Drejer, current CEO, will continue in the role of Chief Scientific Officer of Saniona.

“Rami has a proven track record in a number of areas critical to Saniona, including rare diseases, the US regulatory and market access environment and commercialisation of innovative therapeutics, and are of increasing importance to the company as we seek to bring our highly promising products to markets,” says J. Donald deBethizy, Chairman of the Board of Saniona.

He added: “This is a natural point to step up development of the company, and we are looking forward to continue working with Jørgen in his role as CSO developing our pipeline.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here